tranScrip is delighted to announce the appointment of Emma Chaffin as the Vice President, Head of Commercial Strategy and Portfolio Management.

Emma is a senior commercial leader with over 25 years of pharmaceutical industry experience, that includes consulting and biotech positions of increasing responsibility. Her expertise covers general management and leadership, launch strategy development and implementation, marketing, market access, commercial strategy and commercial effectiveness. Emma joins tranScrip from Galapagos, where she was the Vice President, General Manager & Site Lead for the UK & Ireland affiliates.

Marcin Mankowski, tranScrip’s CEO said: “I am delighted to welcome Emma to tranScrip. Commercial strategy is an inherent part of product lifecycle that needs to be given sufficient attention from the earliest stages of drug development, to avoid costly mistakes and maximise the chances of product’s approval and commercial success. Emma’s appointment strengthens tranScrip’s leadership team and positions us well for the next phase of the company’s growth. Under her leadership, will be able to expand our commercial offering and better serve our clients, providing comprehensive support to their development programmes.

Emma Chaffin said: “I’m delighted to be joining the tranScrip team. At a time when drug development and approval is becoming more and more challenging the tranScrip team offer real value to their clients and I look forward to leading and expanding the Commercial strategy area to help our clients make informed decisions.”